Nicox launches expanded access to Sequenom’s RetnaGene tests in U.S.

Article

Nicox Inc. is launching expanded access to Sequenom Laboratories’ RetnaGene portfolio of genetic tests-RentaGene AMD and RetnaGene LR-which asses an individual’s risk for advanced age-related macular degeneration (AMD).

San Diego, CA-Nicox Inc. is launching expanded access to Sequenom Laboratories’ RetnaGene portfolio of genetic tests-RentaGene AMD and RetnaGene LR-which asses an individual’s risk for advanced age-related macular degeneration (AMD).

“The RetnaGene tests allow for improved patient management, by examining the most relevant genetic markers for a more accurate prediction of advanced AMD risk,” says Jerry St. Peter, executive vice president and general manager of Nicox Inc.

The tests collect DNA specimens with an in-office buccal swab. In January 2014, Sequenom Laboratories granted Nicox exclusive promotion and marketing rights for its RetnaGene tests.

“Currently there is much debate in the medical community surrounding the best way to incorporate genetic testing for AMD into clinical practice. Expanded access to the RetnaGene tests will provide broader use and education to clinicians about this important technology,” said Quan Dong Nguyen, MD, MSc, who holds the McGaw Memorial Endowed Chair in Ophthalmology and is the inaugural director of the Truhlsen Eye Institute, University of Nebraska Medical Center.

Related: AMD genetic testing could lead to early diagnosis, better treatment 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Presenters from the Collaborative Care Symposium 2025 give their key takeaways from their presentations.
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
© 2025 MJH Life Sciences

All rights reserved.